Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 7

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 7
---
 of 2025. For events that occurred during the first quarter of 2025, please refer to Genmab ’ s Q1 2025 report. Detailed descriptions of dosing, efficacy and safety data from certain clinical trials have been disclosed in company announcements and media releases published via the Nasdaq Copenhagen A/S (Nasdaq Copenhagen) stock exchange and may also be found in Genmab’s filings with the U.S. Securities and Exchange Commission (U.S. SEC). Additional information is available on Genmab’s website, www.genmab.com. The information accessible through our website is not part of this report and is not incorporated by reference herein.

#### Genmab Proprietary Products

#### 1

#### Approved Medicines
| Approved Product                            |     | Target             |     | Developed By                 |     | Disease Indication2                                                                                                                                                                                                                                                                                                                                      |
| EPKINLY                                     
 (epcoritamab-bysp, epcoritamab)             
 TEPKINLY                                    
 (epcoritamab)                               |     | CD3xCD20           |     | Co-development               
 Genmab/AbbVie                |     | Approved in multiple territories including in the U.S. and Europe for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy and in Japan for adult patients with certain types of relapsed or refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy |
|                                             |     |                    |     |                              |     | Approved in multiple territories including the U.S., Europe and Japan for adult patients with relapsed or refractory FL after two or more lines of systemic therapy                                                                                                                                                                                      |
| Tivdak                                      
 (tisotumab vedotin-tftv, tisotumab vedotin) |     | Tissue factor (TF) |     | Co-development Genmab/Pfizer |     | Approved in the U.S., Europe and Japan for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy                                                                                                                                                                                                    |

1 Approved and investigational medicines where Genmab has ≥50% ownership, in co-development with partners as indicated.

2 Refer to relevant local prescribing information for precise indication and safety information.

| Genmab A/S            
 Carl Jacobsens Vej 30 
 2500 Valby, Denmark   |     | Tel: +45